富含puerarin的化合物Puerariae lobatae配方通过调节肠道微生物群来增强脏和肠道功能,从而减轻小鼠的高尿血症
Zhi-Xuan Li1, Kai-Wen Kang2, Hao Zheng2
1School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China; School of Pharmacy and Food Engineering, International Healthcare Innovation Institute, Wuyi University, Jiangmen 529020, China.
概括
普埃拉里亚 lobatae 配方和普埃拉林通过增强排泄和修复器官损伤,有效降低尿酸. 它们的治疗效果部分取决于调节肠道微生物群,丰富有益的细菌,如Akkermansia muciniphila.
科学领域:
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
- 微生物学 微生物学
背景情况:
- 在全球范围内,高尿路血症影响超过15%,增加了痛风和心脏病的风险.
- 目前的治疗方法有局限性;像Radix Puerariae Lobatae这样的天然药物提供了更安全的替代品.
研究的目的:
- 调查Puerariae lobatae配方 (PLF1,PLF2) 和 puerarin. 的抗超血性作用.
- 解机制:增强尿酸分泌,修复器官损伤和调节肠道微生物群.
主要方法:
- 通过腺/氧酸盐诱导的高尿素性小鼠模型.
- 用PLF1,PLF2, puerarin或博马龙 (阳性对照) 的治疗.
- 尿酸,酶活动,载体表达 (ABCG2,OAT1),组织学和肠道微生物群 (16S rRNA测序) 的分析.
主要成果:
- PLF1,PLF2和波亚林降低了血尿酸和XOD/ADA活动.
- 改善了脏,肝脏和肠道组织学;升调了ABCG2,OAT1和紧结蛋白.
- 普埃拉林的有效性取决于微生物群,由耗尽和FMT研究证实,丰富了Akkermansia muciniphila.
结论:
- 普埃拉里亚 lobatae 配方和普埃拉林是多目标治疗高尿血症的药物.
- 它们增强尿酸分泌,修复器官损伤,调节肠道微生物群.
- 普埃拉林的微生物群依赖作用突显了其作为一种新型天然治疗剂的潜力.
相关概念视频
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
571
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
571
01:28Gene Regulation in Microbial Communities: Quorum Sensing
92
Quorum sensing is a mechanism of bacterial communication that enables coordinated gene expression in response to changes in population density. This facilitates collective behaviors that enhance survival, resource acquisition, and ecological adaptation. This process relies on small signaling molecules called autoinducers that accumulate as bacterial populations grow. When a critical threshold concentration of autoinducers is reached, bacterial cells collectively modify gene expression,...
92
01:30Peptic Ulcer Disease I: Introduction
289
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
289
01:21Drugs for Treatment of Constipation-Predominant IBS
333
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
333
01:17Drugs for Treatment of Diarrhea-Predominant IBS
294
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
294
01:27Urinary Tract Calculi IV: Nutrition Therapy and Prevention
31
Management of renal calculi focuses on effective strategies like tailored nutrition and hydration therapy. Adjusting diet and fluid intake reduces stone formation and recurrence, making these interventions simple yet powerful in kidney stone prevention and management.Understanding Kidney StonesKidney stones form when calcium, oxalate, uric acid, and cystine concentrate and crystallize in urine. Factors contributing to their formation include genetic predisposition, certain medical conditions,...
31